ACOTEC Scientific Holdings Limited disclosed a swing to a RMB 80.83 million net loss for the six months ended 30 June 2026, reversing a RMB 88.58 million profit a year earlier. The downturn was chiefly driven by a one-off RMB 150.80 million impairment and related provisions following management’s decision to terminate the U.S. IDE clinical programme for the AcoArt Litos® below-the-knee drug-coated balloon (DCB).
\n\nRevenue slipped 5.6 % year on year to RMB 331.58 million. Arterial intervention products—primarily DCBs—fell 32.4 % to RMB 140.78 million, pressured by pricing from China’s Sixth National Volume-Based Procurement (VBP). In contrast, venous intervention, vascular access and other product lines generated RMB 190.80 million, up 36.0 %, buoyed by broader hospital penetration and the October 2025 U.S. launch of the Radiofrequency Ablation System (AcoArt Cedar®).
\n\nGross profit decreased 10.5 % to RMB 233.18 million, with margin narrowing to 70.3 % from 74.2 % due to VBP-linked price cuts and intensified competition. Research and development costs surged 133.8 % to RMB 239.39 million, reflecting the impairment alongside ongoing pipeline investments. Excluding share-based payments, foreign-exchange movements and the impairment, non-IFRS adjusted net profit declined 9.0 % to RMB 90.60 million.
\n\nThe balance sheet remained liquid: cash, time deposits and marketable securities totalled RMB 854.80 million, marginally lower than year-end 2025. Net current assets stood at RMB 1.07 billion, while total equity was RMB 1.40 billion. Bank borrowings were pared to RMB 30.00 million, lifting the gearing ratio to 27.8 %.
\n\nOperationally, ACOTEC’s commercial portfolio reached 32 approved products across five therapeutic areas. Domestic coverage spans more than 3,000 hospitals, and through its partnership with Boston Scientific the company has launched selected peripheral and coronary devices in over 20 overseas markets. During the period, ACOTEC submitted NMPA registration dossiers for embolic microspheres, a lower-limb sirolimus DCB and an intracranial DCB, while its coronary intravascular lithotripsy (IVL) system advanced in clinical trials.
\n\nThe board did not declare an interim dividend.